Knight Therapeutics (TSX:GUD) Institutional Ownership: 23.01% (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:GUD Knight Therapeutics Inc TSX:GUD
73 GF Score
Price C$9.73
GF Value C$8.65
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Institutional Ownership?

Knight Therapeutics TSX:GUD +0.41% 73 Institutional Ownership is 23.01% as of Jul. 24, 2026. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.65 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Knight Therapeutics's institutional ownership is 23.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Knight Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Knight Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Knight Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Institutional Ownership Chart

Knight Therapeutics Historical Data

The historical data trend for Knight Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 20.36 20.53 20.75 23.07 22.77 23.21 23.74 23.71 23.77 23.01
TSX:GUD
73GF Score
Knight Therapeutics Inc TSX:GUD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.01% mean?
Knight Therapeutics (TSX:GUD) has a Institutional Ownership of 23.01% as of Jul. 24, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Institutional Ownership too high?
Knight Therapeutics' current Institutional Ownership is 23.01%. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Institutional Ownership compare to ZTS and UTHR?
Knight Therapeutics' Institutional Ownership of 23.01% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Institutional Ownership is 23.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Modestly Overvalued. The stock's GF Value™ is C$8.65, compared to a current price of C$9.73 — trading 12.5% above its estimated fair value. The current Institutional Ownership is 23.01%. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Institutional Ownership is 23.01% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$9.73 is trading 12.5% above its estimated GF Value™ of C$8.65. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:GUD:

  • Institutional Ownership: 23.01%
  • GF Value™: C$8.65 vs. price of C$9.73 (12.5% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for TSX:GUD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.73
Price
C$8.65
GF Value